Management at Eli Lilly is looking to expand its dealmaking activity through 2020 to create new growth opportunities and long-term value for shareholders. The company is facing some favorable catalysts in the near term from its Phase 3 clinical trials, as well as potential regulatory actions that should offset some near-term patent expirations and boost potential revenue streams.
CareDx has alleged that Natera’s and Viracor’s organ transplant products infringe CareDx’s patent rights. Natera and Viracor argued to the court that those patents are invalid because they cover ineligible subject matter. The magistrate judge has recommended to the district court judge that those arguments be rejected and the motions to dismiss be denied.